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Abstract 1 
Background: The incidence of acute hepatitis C (AHC) among HIV-infected men who 2 
have sex with men (MSM) has increased significantly in the last 10 years. Several 3 
studies point to a social and sexual network of HIV-positive MSM that extends 4 
internationally. 5 
Objectives: The aim of our study was to investigate the dynamics of HCV transmission 6 
in an outbreak of AHC in HIV-infected MSM in Barcelona by ultra-deep pyrosequencing. 7 
Study design: Between 2008 and 2013, 113 cases of AHC in HIV-infected MSM were 8 
diagnosed in the Infectious Diseases Unit, Hospital Clínic, Barcelona. Massive 9 
sequencing was performed using the Roche 454 GS Junior platform. To define possible 10 
transmission networks, maximum likelihood phylogenetic trees were constructed, and 11 
levels of genetic diversity within and among patients were compared. 12 
Results: Among the 70 cases analyzed, we have identified 16 potential clusters of 13 
transmission: 8 for genotype 1a (23 cases involved), 1 for genotype 1b (3 cases) and 7 14 
for genotype 4d (27 cases). Although the initial phylogenetic reconstruction suggested 15 
a local transmission cluster of HCV gt4d, our approach based on low genetic 16 
differentiation did not corroborate it. Indeed, gt4d strains formed 4 independent 17 
groups related to patients from other countries. 18 
Conclusions: Frequent clustering of HIV-positive MSM shows that HCV infection has 19 
spread through a local network in Barcelona. This outbreak is related to a large 20 
international HCV transmission network among MSM. Public health efforts are needed 21 
to reduce HCV transmission among this high-risk group. 22 
Keywords 23 
Acute hepatitis C, HIV-coinfection, HCV transmission, ultra-deep pyrosequencing. 24 
Manuscript Highlighted
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Abbreviations 25 
AHC, acute hepatitis C; ALT, alanine aminotransferase; AST, aspartate 26 
aminotransferase; gt, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency 27 
virus; IDU, intravenous drug users; ML, maximum likelihood; MSM, men who have sex 28 
with men; nt, nucleotide. 29 
  30 
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1. Background and objectives 31 
Hepatitis C virus (HCV) is mainly spread by contact with contaminated blood after 32 
transfusion or by sharing needles with patients who use drugs intravenously. In the 33 
past 10 years, a growing number of cases of acute hepatitis C (AHC) in HIV-positive 34 
men who have sex with men (MSM) have been reported in large urban centers in 35 
Europe [1–6], the United States [7], Asia [8] and Australia [9]. The increased incidence 36 
of AHC in HIV-positive MSM has been attributed to several factors: the tendency 37 
towards a higher HCV viral load in HIV patients’ blood and semen [10], sexual practices 38 
with an increased risk of mucosal damage, the presence of ulcerative sexually 39 
transmitted diseases such as syphilis or lymphogranuloma venereum, a larger number 40 
of sexual partners, and the use of recreational drugs [11]. 41 
In 2009, a phylogenetic analysis of transmitted HCV strains showed clustering 42 
consistent with transmission in a social and sexual network of HIV-positive MSM that 43 
extends internationally [6]. HCV genotype (gt) 4 is the most prevalent genotype in the 44 
Middle East and in Northern and Central Africa, whereas in Europe, North America and 45 
Australia, HCV gt1 and gt3 are the most frequent ones [12]. Nonetheless, several 46 
authors have reported a high rate of HCV gt4d among HIV-positive MSM and identified 47 
monophyletic clusters, which suggests HCV spreading among MSM in Europe [5,13]. 48 
In this study, we have analyzed the transmission dynamics in an epidemic outbreak of 49 
AHC in HIV-positive MSM patients in Barcelona by ultra-deep pyrosequencing. The 50 
initial phylogenetic analyses suggested a single, local transmission cluster of HCV-gt4d. 51 
However, by using a novel approach that took intra- and inter-patient genetic 52 
diversities into account, we showed that this was not the case. Interestingly, this was 53 
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further confirmed because these gt4d HCV strains clustered in separate groups with an 54 
international transmission network of HIV-positive MSM [6]. 55 
 56 
2. Study design 57 
2.1. Study population 58 
The Infectious Diseases Unit of the Hospital Clínic in Barcelona conducts routine 59 
follow-up of HIV-infected patients every 6 months, including clinical, biochemical 60 
evaluation and liver function tests, aspartate aminotransferase (AST) and alanine 61 
aminotransferase (ALT). Anti-HCV antibody testing is performed at the time of 62 
diagnosis of HIV infection, every two years, and whenever patients report risk factors 63 
for HCV infection. All patients who have an unexplained increase in liver enzyme 64 
activities (more than twice the upper normal limit) during routine monitoring of HIV 65 
infection and all patients with clinical signs of acute hepatitis (jaundice, severe fatigue, 66 
urine and stool discoloration) are screened for serum anti-HCV and HCV-RNA levels. 67 
Between January 2008 and December 2013, 113 episodes of AHC in HIV-infected MSM 68 
were diagnosed at our center [3]. Serum samples were available from 84 cases of AHC 69 
that occurred in 79 patients. For comparison purposes, we included a control group 70 
consisting of 29 chronic hepatitis C patients diagnosed in the area of Barcelona and 71 
including all the genotypes involved in the AHC cases. The study was approved by the 72 
Ethics Committee of the Hospital Clínic, Barcelona, and all the participants provided 73 
written informed consent. 74 
 75 
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2.2. HCV-NS5B amplification for ultra-deep pyrosequencing 76 
To analyze the dynamics of transmission in our cohort, a fragment of 340 bp of the 77 
HCV-NS5B region (from nucleotides 8279 to 8618, isolate H77, accession AF009606) 78 
was amplified and massively sequenced as previously described [14]. Data treatment 79 
was performed using the pipelines designed to obtain clean nucleotide haplotypes [15] 80 
and for HCV subtyping [14]. Full details of the PCR strategy and ultra-deep 81 
pyrosequencing are provided as Supplementary Materials and Methods. 82 
2.3. HCV-NS5B amplification for direct sequencing 83 
In order to establish the relationships between the AHC cases reported here and an 84 
international sexual transmission network of HIV-positive MSM [6], we amplified and 85 
directly sequenced another fragment of 430 bp of the NS5B region (from nucleotides 86 
8553 to 8982of the H77 reference sequence) as described elsewhere [16,17], but with 87 
some modifications (additional details in Supplementary Materials and Methods). 88 
2.4. Phylogenetic analysis 89 
Multiple alignments were performed with ClustalW [18]. Maximum likelihood (ML) 90 
trees were obtained with PhyML [19], using the GTR+Gamma substitution model as 91 
determined by Modeltest v.3.8 [20]. Support for the internal nodes was evaluated with 92 
1,000 bootstrap replicates [21]. Genetic diversity (intra- and inter-patient) was 93 
calculated with Arlequin [22]. For the analysis of deep pyrosequencing data, we only 94 
considered haplotypes with abundances above 0.5%. 95 
To strengthen the identification of groups of transmission, we combined phylogenetic 96 
clustering in the ML trees with the analysis of the net inter-patient genetic diversity 97 
compared to the intra-patient genetic diversity in each group. We defined the net 98 
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inter-patient genetic diversity as the total genetic diversity of a group minus the 99 
weighted average of the intra-patient diversities of the samples included in that group. 100 
By using this approach, clusters in the phylogenetic tree must fulfill two conditions to 101 
be considered as transmission groups: 1) high bootstrap support (≥80%) and 2) the net 102 
inter-patient genetic diversity of their sequences (i.e. among the members of the 103 
cluster) should be lower than the highest intra-patient diversity in the same genotype. 104 
2.5. Nucleotide sequence accession numbers 105 
NS5B sequences obtained in this study have been deposited in GenBank under 106 
accession numbers SAMN06289805 to SAMN06289918 (deep sequencing, SRA 107 
database BioProject PRJNA369605) and KY674814 to KY674856 (Sanger sequencing). 108 
 109 
3. Results 110 
3.1. Baseline characteristics of patients 111 
Patient characteristics at the time of AHC diagnosis are shown in Table 1. The median 112 
age was 39 years (range 34-44). In two cases, AHC and HIV diagnoses were 113 
concomitant. Sixty-four patients were receiving combined antiretroviral therapy 114 
before AHC diagnosis. At the time of AHC diagnosis, all but one patient had 115 
undetectable HIV viral load, and median HCV-RNA was 6.28 Log IU/mL (range 4.78-116 
6.66). The prevalence of HCV genotypes was: 43 (51%) gt4d, 33 (39%) gt1a, 7 (8%) gt1b 117 
and 1 (1%) gt3a (the latter was excluded from the ensuing analyses). Among the 84 118 
AHC cases, 5 were reinfected with a different HCV genotype from that of the first 119 
episode (Supplementary Table S1). 120 
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3.2. Phylogenetic analysis of HCV quasispecies 121 
The HCV NS5B gene was successfully amplified and sequenced in 70 AHC cases (32 122 
gt1a, 4 gt1b and 34 gt4d) and in the 29 local controls (8 gt1a, 7 gt1b and 14 gt4d). 123 
Ultra-deep pyrosequencing yielded 225,698 reads from haplotypes with abundance 124 
above 0.5%, with a median average coverage of 2,280 reads per sample 125 
(Supplementary Table S2). Notably, no multiple HCV infections were found in any of 126 
the cases analyzed. 127 
To identify monophyletic clusters, we constructed ML trees for each genotype (Fig. 1). 128 
Based on phylogenetic clustering (bootstrap support >80%), several putative 129 
transmission clusters could be identified: 16 for gt1a (A to P, Fig. 1a), 2 for gt1b (A and 130 
B, Fig. 1b) and 12 for gt4d (A to L, Fig. 1c). Interestingly, all gt4d AHC patients clustered 131 
separately from the local controls in a well-supported clade. This was not the case for 132 
gt1a and gt1b AHC patients, for which several clusters contained sequences from the 133 
local controls. These observations suggested a single source of infection for gt4d in our 134 
study cohort.  135 
In order to assess whether the monophyletic groups identified by phylogenetic 136 
clustering corresponded to actual transmission clusters, we considered that low net 137 
genetic differentiation was an indicator of close epidemiological relatedness. First, we 138 
computed the intra-patient genetic diversity for all the samples. The results indicated 139 
that the local controls had the highest genetic diversity in all cases (Supplementary 140 
Table S3). Next, we determined the net genetic diversity among AHC cases included in 141 
the clusters identified in the ML tree (Supplementary Table S4). For gt1a, we identified 142 
8 groups (B, C, F, G, H, I J and K, Fig. 1a) which had a net genetic diversity lower than 143 
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the maximum intra-patient value for this genotype (0.00944, control K3786). These 144 
clusters included 5 patients at most. Cluster F was composed of subclusters D and E 145 
and thus, they should be considered as a single transmission group. Likewise, only one 146 
cluster of transmission was considered for gt1b, which included 3 of the 5 gt1b 147 
analyzed patients (group A, Fig. 1b)  148 
As mentioned before, all gt4d sequences clustered into a single clade with high 149 
statistical support (group A, Fig. 1c). However, since its net divergence (0.01468) was 150 
larger than the maximum intra-patient diversity for this subtype (0.01165, control 151 
K2876), it could not be considered as a single cluster of transmission. A similar result 152 
was obtained for group B, which included 16 patients, with a net diversity of 0.01537. 153 
Thus, for gt4d, we observed 7 clusters (C, F, G, I, J, K and L, Fig. 1c) in which between 2 154 
to 9 patients were involved.  155 
3.3. Comparison of genotype 4d with the international network 156 
Previous works have described a large, multinational network of HCV gt4d spreading 157 
among MSM in several European countries [5,13]. To compare the gt4d sequences 158 
from our study with those from the international network, we amplified and 159 
sequenced another region of the NS5B as reported previously [6,16]. 160 
As shown in Fig 2, the ML tree derived from this international network of HCV 161 
transmission and our local AHC and control sequences of gt4d clearly confirmed that 162 
the AHC monophyletic group observed hitherto (group A, Fig. 1c) was no longer a 163 
cluster of transmission. In particular, sequences from patients p45, p49, p51, p53, p57, 164 
p62 and p64 clustered with high bootstrap support with sequences from Germany, the 165 
Netherlands and France. These sequences also represented three independent 166 
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introductions: 1) p45 and p62; 2) p49, p51, p57 and p64; and 3) p53, in addition to the 167 
group encompassing exclusively sequences from the remaining gt4d AHC patients. The 168 
sequences from local controls were related only to one sequence obtained from the 169 
international MSM network. 170 
 171 
4. Discussion 172 
As observed in several cities in Europe, North America and Australia, the incidence of 173 
AHC among HIV-positive MSM has also increased exponentially in Spain during the last 174 
10 years [2,3,23,24]. However, phylogenetic data in this group of patients are scarce 175 
[25]. In this study, we have analyzed the network of transmission of an AHC epidemic 176 
outbreak in HIV-infected MSM in Barcelona by ultra-deep pyrosequencing. In our 177 
cohort, we identified 5 patients with one further AHC episode with a different HCV 178 
genotype from that of the prior infection. Reinfection rate was 6%, somewhat less 179 
than in previous studies, most probably due to shorter follow-ups, but still indicating 180 
the lack of immune protection after HCV infection [26,27]. 181 
For epidemiologists, clusters represent an urgent need to intervene on focal groups to 182 
prevent further spread and risk for the general population and, for these reasons, their 183 
identification is relevant. However, from a molecular epidemiology point of view there 184 
are many possible definitions of transmission cluster. Grabowski and Redd [28] 185 
reviewed and summarized cluster definitions from 20 phylogenetic studies of HIV 186 
transmission. Indeed, only 3 studies considered the same definition and that was the 187 
least stringent of all: 70% bootstrap support in a ML or neighbor joining tree. In a 188 
recent study based on consensus Sanger sequencing, Lamoury et al. showed that the 189 
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use of longer HCV sequences increased the accuracy of cluster identification [29]. 190 
Alternatively, deep sequencing of shorter fragments along with phylogenetic analyses 191 
have also been applied in different settings to explore the relationships between 192 
infected individuals [30–33]. In particular, NS5B deep sequencing has been shown to 193 
improve the discrimination of clusters versus consensus Sanger sequencing analysis 194 
when applying dynamic patristic distance thresholds based upon each individual's 195 
intra-host viral population [33]. 196 
Here, we have introduced a new criterion to fine tune the identification of 197 
transmission clusters after deep sequencing of a short fragment. We have compared 198 
the net inter-patient genetic diversity among sequences from patients putatively 199 
included in a cluster, because of strong grouping in a phylogenetic reconstruction (high 200 
bootstrap in the ML tree), with the intra-patient diversity of a local control group of 201 
chronic hepatitis C patients. We assumed that the largest intra-patient diversity 202 
represented a reasonable upper limit to consider sequences with a lower net inter-203 
patient diversity among them as involved in a transmission chain. By applying this 204 
criterion, we have identified 16 potential clusters of transmission: 8 for gt1a (23 cases 205 
involved), 1 for gt1b (3 cases) and 7 for gt4d (27 cases). 206 
Using intra-patient diversity from individuals with chronic HCV infection may be a 207 
limitation, because the longer the chronic infection in a patient, the higher the 208 
diversity of the viral population. Nonetheless, in our study cohort, the criterion of the 209 
largest intra-patient diversity as an upper limit to consider closely related sequences 210 
proved to be more accurate than those based on statistical support of the groupings. 211 
For instance, both groups L and O in gt1a included various subclusters that fit well 212 
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within the adopted definition of transmission clusters because of their low net 213 
diversity (subclusters J and K for group L, and subclusters B, C, D, E and F for group O). 214 
However, groups L and O/P also included control patients such as K2084 in group L and 215 
K0417 in groups O/P, which suggested that those groups might not be MSM 216 
transmission clusters. According to this observation, the net divergences of groups L, O 217 
and P were higher than the corresponding upper limit and thus, they were not 218 
considered as transmission clusters. 219 
Recent studies emphasize that gt4d is highly prevalent among intravenous drug users 220 
(IDU) and HIV-positive MSM [5,6,13,16]. Indeed, the homogeneity of these strains 221 
suggests that gt4d was introduced in the European IDU population quite recently, 222 
entering the MSM population afterwards [11,16]. Our data show that 7 of our gt4d 223 
AHC sequences grouped with sequences from this international network with at least 3 224 
independent introductions, indicating that the outbreak in Barcelona is highly related 225 
to previously described European MSM transmission clusters [6]. The existence of 226 
epidemiological networks of HCV transmission among HIV-positive MSM has also been 227 
confirmed in a recent study in which two clusters of AHC samples were highly related 228 
to gt1a isolates from Germany, the Netherlands, United Kingdom and Australia, 229 
belonging to the above mentioned transmission network [25]. 230 
One of the main limitations of the study is its retrospective nature, which limits the 231 
epidemiological information, and has prevented us from identifying and dating the 232 
source of the outbreak, particularly for gt4d. To collect data on social behavior and the 233 
common leisure-oriented public places, self-administered questionnaires were given to 234 
the patients. However, only half of them filled the forms completely and most 235 
12 
 
admitted being under the effect of recreational drugs, making it difficult to trace 236 
common social habits.  237 
In conclusion, our findings show that HCV infection has spread rapidly among HIV-238 
infected MSM through a local network in Barcelona. Frequent clustering of gt4d AHC 239 
patients with other European HIV-coinfected cases demonstrates that this outbreak is 240 
related to an interconnected transmission network of transnational MSM communities. 241 
The implementation of public health campaigns and preventive measures, as well as 242 
treatment interventions with the new direct-acting antivirals will allow the 243 
development of strategies to reduce HCV transmission within these high-risk groups. 244 
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Figure Legends 377 
 378 
Fig. 1. Maximum likelihood trees were constructed for each genotype separately: (a) 379 
gt1a, (b) gt1b and (c) gt4d. Only sequences with relative frequency >0.5% in the 380 
corresponding sample were included in the analyses. AHC HIV-coinfected patients are 381 
identified as pXX, where XX represents a number from 1 to 84, and control patients are 382 
identified as kXXXX, were XXXX represents a 4 digit number. Bootstrap support values 383 
>80% are indicated in the corresponding nodes. Triangle areas are proportional to the 384 
diversity and frequency of the different haplotypes (quasiespecies) in a sample. Capital 385 
letters (black) indicate potential transmission clusters analyzed in more detail in 386 
Supplementary Table S4. 387 
Fig. 2. Maximum likelihood tree constructed with HCV gt4d sequences derived from 388 
the international network reported by Van de Laar et al. (2009) and from our study 389 
cohort of AHC HIV-coinfected MSM. Patients in our study cohort are identified as pXX, 390 
for HAC (red), or kXXXX, for local controls (brown). Patients from the international 391 
network were denoted as reported: FP, France (blue); ELR, ELC and EB, United 392 
Kingdom (grey); S, NR, NA and PP, The Netherlands (purple); GB, Germany (green). 393 
Nodes with bootstrap >80% are indicated in the tree. 394 
Table 1. Patient characteristics at the time of AHC diagnosis. 
 
AHC cases (n= 84) 
Age (years) 39 (34-44) 
Years between HIV and HCV diagnoses 5.6 (0.1-8.6) 
Baseline CD4 (cells/L) 564 (454-742) 
Baseline % CD4 29 (21-34) 
Baseline HIV viral load (IU/mL) Undet* 
Antiretroviral therapy 64 (76%) 
Symptoms 23 (27%) 
HCV-RNA (Log IU/mL) 6.28 (4.78-6.66) 
AST (IU/L) 191 (102-329) 
ALT (IU/L) 460 (224-702) 
HCV Genotype: 
 
1a 33 (39%) 
1b 7 (8%) 
3a 1 (1%) 
4d 43 (51%) 
Other sexually transmitted diseases 36 (43%) 
Interval diagnoses-start therapy (months) 2.0 (1.5-2.6) 
PegIFN therapy 66 (79%) 
Sustained virological response 45 (68%) 
Quantitative variables are shown as median (range) and qualitative variables are 
shown as n (%). 
Undet, Undetectable HIV viral load (Limit of detection= 37 IU/mL) 
* One patient had very low HIV viral load of 67 IU/mL. 
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HCV-NS5B amplification for ultra-deep pyrosequencing 
Amplification and ultra-deep pyrosequencing of a 340 bp fragment of the HCV-NS5B 
region (nt 8279 to 8618, according to the isolate H77, data available in Genbank under 
accession number AF009606) was performed as previously described (1). HCV-RNA was 
extracted from 140 μL of serum by manual RNA extraction using the QIAamp viral RNA 
minikit (Qiagen, Hilden, Germany), as specified by the manufacturer. RT-PCR was 
performed using Transcriptor One Step RT-PCR Kit (Roche Applied Science Basel, 
Switzerland), using 20 pmol of sense primer 5Bo8254 and antisense primer 5Bo8707. 
Reverse transcription was performed at 50ºC for 30 min followed by a 2-step PCR reaction 
including: denaturing for 7 min at 94ºC; a first step of 10 cycles of 10 s at 94ºC, 30 s at 
50ºC, and 1 min at 68ºC; a second step of 25 cycles of 10 s at 94ºC, 30 s at 50ºC and 1 min 
at 68ºC, increasing extension time 5 s per cycle; a final 7 min step at 68ºC. 
Hemi-nested-PCR was performed using Fast Start High Fidelity PCR System, dNTPack 
(Roche Applied Science Basel, Switzerland). Briefly, 5μL from the previous PCR were 
amplified by a second PCR using sense primer 13n5Bo8254 and antisense primer 
13n5Bo8641. These primers are composed by universal M13 forward and M13 reverse at 
5' ends followed by a specific fragment complementary of the HCV PCR product amplified 
in the first round (see List of Primers below). Nested-PCR conditions were the following: 
denaturing for 2 min at 95ºC; 35 cycles of 30 s at 95ºC, 30 s at 55ºC and 1 min at 72ºC; a 
final 7 min step at 72ºC. For sample identification, the final product of the hemi-nested 
Supplementary Materials and Methods
amplification, was subjected to 15-cycles of re-amplification using primers composed by a 
complementary universal M13 primer (either sense or antisense) followed by a Roche's 
Validated Multiplex Identifier (MID) and with oligo A or B at 5' or 3' end of the sense or 
antisense primer, respectively. 
 
Ultra-deep pyrosequencing and data treatment 
Massive sequencing was performed in the GS-Junior 454/Roche platform (Roche, 
Branford, CT, USA), using titanium chemistry, which enables sequencing of 400- to 500-nt 
fragments (GS Junior Titanium Sequencing Kit), following manufacturer recommendations. 
The data used for the analysis was the FASTA files obtained from the 454 GS Junior 
system’s software, which applies stringent quality controls on each sequenced nucleotide 
to guarantee the integrity of the full length of the amplicon. Briefly, the sequences were 
first demultiplexed by identifying MID and specific primer for each strand, and quality 
filtered by excluding all haplotypes with more than two Ns (any base), three gaps, not 
covering the full amplicon, or with an identity below 67% relative to the master sequence 
(defined here as the most abundant haplotype in the corresponding population). The 
accepted haplotypes with Ns and/or gaps were repaired by comparison with the dominant 
haplotype. Data treatment was performed using the pipelines designed to obtain clean 
nucleotide haplotypes (2) and for HCV subtyping (1). 
  
HCV-NS5B amplification for Sanger direct sequencing 
HCV-RNA was purified as described above. HCV-NS5B amplification of a 430 bp fragment 
of the HCV-NS5B region (nt 8553 to 8982 according to the isolate H77, data available in 
Genbank under accession number AF009606) was performed as described elsewhere (3,4) 
with some modifications. Briefly, cDNA was synthesized using genotype-specific primer 
4HCV-OA (see List of Primers below) and AMV at 42ºC for 60 minutes in the presence of 
RNAsin (Pomega, Madison, WI). 5 μl of cDNA were used as template in a first-round PCR 
containing NS5B outer primers 4HCV-OS (sense) and 4HCV-OA (antisense), and 1.05 U of 
Expand High Fidelity Taq polymerase (Roche Applied Science). PCR cycling conditions 
were: 5 min at 95ºC, 35 cycles at 95ºC for 30 s, 50ºC for 30 s and 72º C for 1 min and a 
final extension of 7 min at 72ºC. 5 μl of the first-round product were then used in second-
round reactions, using identical conditions as for the first-round and inner primers 4HCV-
IS (sense) and E1b (I/A) (antisense). 
PCR products were purified using the QIAquick PCR purification kit (Qiagen, Hilden, 
Germany). In order to obtain the population sequence (direct sequence), 20-50 ng of 
purified PCR product were sequenced bi-directionally using the set of primers of the 
corresponding nested (inner) PCR and the Big Dye Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems, Foster City, CA, USA).  
All extractions and amplifications were run according to universally adopted precautions, 
such as the use of different rooms for pre-PCR experiments and post-PCR experiments, in 
order to avoid cross-contamination. Negative controls for each step of RNA extraction and 
amplification were included.  
List of Primers 
Primer ID Primer Sequence (5'→3') 
Nucleotide 
Position* 
5Bo8254 CNTAYGAYACCMGNTGYTTTGACTC 8254-8278 
5Bo8707 TTNGADGAGCADGATGTWATBAGCTC 8682-8707 
13n5Bo8254 GTTGTAAAACGACGGCCAGTCNTAYGAYACCMGNTGYTTTGACTC 8256-8278 
13n5Bo8641 CACAGGAAACAGCTATGACCGARTAYCTGGTCATAGCNTCCGTGAA 8619-8641 
4HCV-OS ACCACCAGCTTYGGRAACAC 8457-8476 
4HCV-OA TTCGTGTGGAGAGTATCCRTGCA 9022-9044 
4HCV-IS CTGAGAGACTGCACSATGYTGGT 8523-8545 
E1b (I/A) AATGCGCTRAGRCCATGGAGTC 8995-9016 
 
*Nucleotide position according to isolate H77, accession number AF009606 
Primer sequences in italics correspond to M13 universal primers 
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Supplementary Tables 
 
Table S1. HCV reinfection episodes. 
Episode Cases involved Date of diagnosis HCV genotype 
Episode 1 
p5 02/05/2011 1b 
p23 12/11/2012 4d 
Episode 2 
p69 10/06/2009 1a 
p7 08/08/2011 4d 
Episode 3 
p25 01/06/2012 1b 
p49 05/09/2013 4d 
Episode 4 
p57 16/10/2013 4d 
p58 26/04/2011 1a 
Episode 5 
p61 10/06/2009 4d 
p50 10/05/2013 1b 
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Table S2. Number of reads (forward + reverse) per sample, belonging to haplotypes 
with abundance above 0.5%. Control patients are shaded in blue. 
HCV genotype 1a 
Case Reads Case Reads 
p1 1622 p66 4177 
p3 1469 p68 1912 
p6 1261 p69 1265 
p14 11558 p70 961 
p21 1524 p71 763 
p27 620 p72 3161 
p28 379 p73 7112 
p30 952 p78 1093 
p32 612 p79 4919 
p37 773 p80 3070 
p39 311 p83 4559 
p40 572 p84 7522 
p41 4267 K3523 2042 
p43 4131 K3786 4228 
p56 6008 K4157 2421 
p58 3409 K4213 5825 
p59 2287 K4572 11059 
p60 1252 K0398 1235 
p63 2311 K0417 2155 
p65 5638 K2084 312 
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Cont. Table S2. 
HCV genotype 1b 
Case Reads Case Reads 
p5 3284 K3602 731 
p9 804 K3607 358 
p25 1463 K3716 404 
p50 6701 K3741 330 
K3582 4280 K3181 1627 
K3594 1357   
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Cont. Table S2. 
HCV genotype 4d 
Case Reads Case Reads 
p2 889 p55 449 
p4 1859 p57 3752 
p7 701 p61 376 
p10 822 p62 468 
p11 429 p64 1969 
p17 4872 p67 1318 
p18 3519 p75 2735 
p19 840 p77 9390 
p20 313 p81 2828 
p22 854 p82 927 
p23 779 K0075 387 
p24 358 K0874 2708 
p26 521 K0997 1450 
p29 898 K1139 412 
p31 526 K1702 3330 
p33 446 K2238 1641 
p35 3141 K2457 710 
p44 627 K2488 590 
p45 697 K2690 686 
p46 3741 K2761 887 
p49 1717 K2876 699 
p51 6859 K3071 4267 
p53 1025 K3363 1371 
p54 567 K3476 3262 
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Table S3. Intra-patient genetic diversity in chronic hepatitis C (local controls) and AHC-
HIV co-infected patients (AHC). 
Genotype Patients Average Maximum Minimum 
1a 
Controls (n=8) 0.00260 0.00944 0.00015 
AHC (n=32) 0.00112 0.00457 0.00007 
1b 
Controls (n=7) 0.00632 0.01035 0.00154 
AHC (n=4) 0.00150 0.00214 0.00022 
4d 
Controls (n=14) 0.00552 0.01165 0.00101 
AHC (n=34) 0.00076 0.00212 0.00000 
Genetic differentiation was calculated as the number of nt substitutions per site. 
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Table S4. Total and net genetic differentiation (substitutions/site) among cases in 
groups of AHC samples. Non-overlapping clusters are shaded in blue. 
HCV genotype 1a Total 
diversity 
Net 
diversity Groups Cases included 
A p1, p59 0.02208 0.02137 
B p14, p60 0.00306 0.00194 
C p3, p63 0.00332 0.00277 
D (subcluster)* p30, p41 0.00089 0.00001 
E (subcluster)* p37, p78, p84 0.00169 0.00046 
F p30, p41, p37, p78, p84 0.00929 0.00805 
G p28, p58 0.00072 0.00055 
H p21, p32, p39, p40 0.00111 0.00023 
I p56, p68, p79, p80 0.00877 0.00760 
J p70, p73 0.00285 0.00247 
K p66, p72 0.00262 0.00037 
L** p70, p73, p66, p72 0.01112 0.00985 
M p70, p73, p66, p72, p71 0.01119 0.00996 
N P65, p69 0.01716 0.01667 
O** p1, p59, p14, p60, p3, p63, p30, p41, p37, 
p78,p84, p83, p27, p28, p58 
0.03936 0.03835 
P** p1, p59, p14, p60, p3, p63 0.02282 0.02188 
* Group F is divided in 2 subclusters: groups D and E. Thus, they should be considered as a 
single group of transmission. 
** Groups L, O and P were incorporated in the net diversity analysis despite the fact that they 
included one control patient because a priori we cannot exclude its relationship with the 
transmission network. 
 
HCV genotype 1b Total 
diversity 
Net 
diversity Groups Cases included 
A p9, p25, p5 0.01160 0.01006 
B (subcluster) p9, p25 0.00076 0.00008 
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Cont. Table S4. 
HCV genotype 4d Total 
diversity 
Net 
diversity Groups Cases included 
A All HCV-4d AHC patients (n=34) 0.01581 0.01468 
B 
p2, p4, p10, p17, p23, p29, p33, p45, 
p49, p51, p55, p57, p62, p64, p67, p82 
0.01626 0.01537 
C 
p2, p4, p10, p17, p23, p29, p33, p55, 
p67 
0.00738 0.00651 
D (subcluster) p4, p17, p23, p29, p33, p55, p67 0.00399 0.00317 
E (subcluster) p2, p10  0.00516 0.00441 
F p22, p31, p44, p54, p81 0.00299 0.00225 
G p45, p51, p62, p64, p82 0.01016 0.00840 
H (subcluster) p45, p62, p82 0.00226 0.00155 
I p35, p46 0.00023 0.00001 
J p18, p61 0.00303 0.00104 
K p24, p77 0.00178 0.00103 
L p19, p26 0.00173 0.00140 
 
 
